10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(MARK ONE)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED June 30, 2013

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM              TO             

COMMISSION FILE NUMBER 1-11151

U.S. PHYSICAL THERAPY, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

NEVADA	76-0364866
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)	(I.R.S. EMPLOYER IDENTIFICATION NO.)

1300 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 300, HOUSTON, TEXAS	77042
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)	(ZIP CODE)

REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (713) 297-7000

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    x  Yes    ¨  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    x  Yes    ¨  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ¨  Yes    x  No

As of August 8, 2013, the number of shares outstanding (issued less treasury stock) of the registrant’s common stock, par value $.01 per share, was: 12,106,424.

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements.
	Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012	3
	Consolidated Statements of Net Income for the three months and six months ended June 30, 2013 and 2012	4
	Consolidated Statements of Cash Flows for the six months ended June 30, 2013 and 2012	5
	Consolidated Statement of Shareholders’ Equity for the six months ended June 30, 2013	6
	Notes to Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	25
Item 4.	Controls and Procedures	26
PART II - OTHER INFORMATION
Item 6.	Exhibits	26
	Signatures	27
	Certifications	25-28

2

ITEM 1. FINANCIAL STATEMENTS.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE DATA)

	June 30, 2013			December 31, 2012
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	10,287		$	11,671
Patient accounts receivable, less allowance for doubtful accounts of $1,469 and $1,595, respectively		27,564			25,973
Accounts receivable - other, less allowance for doubtful accounts of $412 and $514, respectively		1,700			1,703
Other current assets		1,878			5,975
Total current assets		41,429			45,322
Fixed assets:
Furniture and equipment		37,941			36,316
Leasehold improvements		21,404			20,858
		59,345			57,174
Less accumulated depreciation and amortization		45,588			44,158
		13,757			13,016
Goodwill		112,248			100,188
Other intangible assets, net		14,029			12,146
Other assets		967			1,042
	$	182,430		$	171,714
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable - trade	$	1,275		$	1,732
Accrued expenses		15,298			14,116
Current portion of notes payable		800			459
Total current liabilities		17,373			16,307
Notes payable		400			175
Revolving line of credit		15,750			17,400
Deferred rent		972			894
Other long-term liabilities		706			2,279
Total liabilities		35,201			37,055
Commitments and contingencies
Shareholders’ equity:
U. S. Physical Therapy, Inc. shareholders’ equity:
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding		—			—
Common stock, $.01 par value, 20,000,000 shares authorized, 14,319,911 and 14,129,651 shares issued, respectively		143			141
Additional paid-in capital		38,571			37,489
Retained earnings		117,538			111,321
Treasury stock at cost, 2,214,737 shares		(31,628	)		(31,628	)
Total U. S. Physical Therapy, Inc. shareholders’ equity		124,624			117,323
Noncontrolling interests		22,605			17,336
Total equity		147,229			134,659
	$	182,430		$	171,714

See notes to consolidated financial statements.

3

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF NET INCOME

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Net patient revenues	$	65,295		$	62,052		$	126,800		$	122,551
Other revenues		1,929			1,907			3,522			3,990
Net revenues		67,224			63,959			130,322			126,541
Clinic operating costs:
Salaries and related costs		35,813			32,671			70,228			65,470
Rent, clinic supplies, contract labor and other		12,904			12,992			25,822			25,476
Provision for doubtful accounts		1,193			1,280			2,282			2,397
Closure costs		8			22			26			71
Total clinic operating costs		49,918			46,965			98,358			93,414
Gross margin		17,306			16,994			31,964			33,127
Corporate office costs		6,622			6,396			13,129			12,658
Operating income		10,684			10,598			18,835			20,469
Interest and other income, net		1			1			3			3
Interest expense		(130	)		(145	)		(265	)		(307	)
Income before taxes		10,555			10,454			18,573			20,165
Provision for income taxes		3,181			3,140			5,590			6,039
Net income including noncontrolling interests		7,374			7,314			12,983			14,126
Less: net income attributable to noncontrolling interests		(2,460	)		(2,465	)		(4,348	)		(4,799	)
Net income attributable to common shareholders	$	4,914		$	4,849		$	8,635		$	9,327
Earnings per share attributable to common shareholders:
Basic	$	0.41		$	0.41		$	0.72		$	0.79
Diluted	$	0.41		$	0.41		$	0.72		$	0.79
Shares used in computation:
Basic		12,089			11,781			12,022			11,754
Diluted		12,110			11,903			12,044			11,872
Dividends declared per common share	$	0.10		$	0.09		$	0.20		$	0.18

See notes to consolidated financial statements.

4

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(unaudited)

	Six Months Ended June 30,
	2013			2012
OPERATING ACTIVITIES
Net income including noncontrolling interests	$	12,983		$	14,126
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization		2,730			2,646
Provision for doubtful accounts		2,282			2,397
Equity-based awards compensation expense		1,370			1,043
Loss on sale or abandonment of assets, net		84			83
Deferred income tax		(796	)		1,046
Other		33			—
Changes in operating assets and liabilities:
Increase in patient accounts receivable		(2,542	)		(1,613	)
Decrease (increase) in accounts receivable - other		4			(400	)
Decrease in other assets		3,867			301
Increase (decrease) in accounts payable and accrued expenses		682			(693	)
Increase in other liabilities		19			31
Net cash provided by operating activities		20,716			18,967
INVESTING ACTIVITIES
Purchase of fixed assets		(2,394	)		(1,943	)
Purchase of businesses, net of cash acquired		(9,998	)		(7,180	)
Acquisitions of noncontrolling interests, net of sales		(1,064	)		(726	)
Net proceeds on sale of fixed assets and business		15			28
Net cash used in investing activities		(13,441	)		(9,821	)
FINANCING ACTIVITIES
Distributions to noncontrolling interests		(4,410	)		(4,751	)
Cash dividends to shareholders		(2,418	)		(2,117	)
Proceeds from revolving line of credit		62,550			32,400
Payments on revolving line of credit		(64,200	)		(35,900	)
Payment of notes payable		(234	)		(184	)
Excess tax benefit from stock options exercised		33			184
Other		20			50
Net cash used in financing activities		(8,659	)		(10,318	)
Net decrease in cash		(1,384	)		(1,172	)
Cash - beginning of period		11,671			9,983
Cash - end of period	$	10,287		$	8,811
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for:
Income taxes	$	1,999		$	3,886
Interest	$	237		$	422
Non-cash investing and financing transactions during the period:
Purchase of business - seller financing portion	$	800		$	350

See notes to consolidated financial statements.

5

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

(IN THOUSANDS)

(unaudited)

	U. S. Physical Therapy, Inc.
	Common Stock				Additional Paid-In Capital			Retained Earnings			Treasury Stock						Total Shareholders’ Equity			Noncontrolling Interests
	Shares		Amount								Shares			Amount									Total
Balance December 31, 2012		14,130	$	141	$	37,489		$	111,321			(2,215	)	$	(31,628	)	$	117,323		$	17,336		$	134,659
Issuance of restricted stock		175		—		—			—			—			—			—			—			—
Compensation expense - restricted stock		—		—		1,370			—			—			—			1,370			—			1,370
Transfer of compensation liability for certain stock issued pursuant to incentive plans		—		—		248			—			—			—			248			—			248
Proceeds from exercise of stock options		15		2		18			—			—			—			20			—			20
Excess tax benefit of equity grants		—		—		33			—			—			—			33			—			33
Purchases of business		—		—		—			—			—			—			—			5,428			5,428
Acquisition of non controlling interests		—		—		(587	)		—			—			—			(587	)		(97	)		(684	)
Cash dividends to shareholders		—		—		—			(2,418	)		—			—			(2,418	)		—			(2,418	)
Distributions to noncontrolling interest partners		—		—		—			—			—			—			—			(4,410	)		(4,410	)
Net income		—		—		—			8,635			—			—			8,635			4,348			12,983
Balance June 30, 2013		14,320	$	143	$	38,571		$	117,538			(2,215	)	$	(31,628	)	$	124,624		$	22,605		$	147,229

See notes to consolidated financial statements.

6

U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2013

(unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries (the “Company”). All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest and a 64% limited partnership interest. The managing therapist of each clinic owns, directly or indirectly, the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as “Clinic Partnership”). To a lesser extent, the Company operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with therapists (hereinafter referred to as “Wholly-Owned Facilities”).

The Company continues to seek to attract physical and occupational therapists who have established relationships with patients and physicians by offering therapists a competitive salary and a share of the profits of the clinic operated by that therapist. The Company has developed satellite clinic facilities of existing clinics, with the result that many Clinic Partnerships and Wholly-Owned Facilities operate more than one clinic location. In addition, the Company has acquired a majority interest in a number of clinics through acquisitions.

During the six months ended June 30, 2013, the Company acquired the following clinic groups:

Acquisition	Date	% Interest Acquired	Number of Clinics
February 2013 Acquisition	Feb 28	72%	9
April 2013 Acquisition	Apr 30	50%	5
May 2013 Acquisition	May 24	80%	5

In addition to the above clinic group acquisitions, the Company, through two of its subsidiaries, acquired two physical therapy clinic practices in two separate transactions (the “Tuck-In Acquisitions”).

As of June 30, 2013, the Company operated 449 clinics in 43 states.

The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.

The Company intends to continue to focus on developing new clinics, on opening satellite clinics where deemed appropriate and pursuing additional acquisition opportunities.

The accompanying unaudited consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions for Form 10-Q. However, the statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. Management believes this report contains all necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. For further information regarding the Company’s accounting policies, please read the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate Controller have certified, that the financial statements included in this report present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented.

Operating results for the three and six months ended June 30, 2013 are not necessarily indicative of the results the Company expects for the entire year. Please also review the Risk Factors section included in our Annual Report on Form 10-K for the year ended December 31, 2012.

7

Clinic Partnerships

For Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interests, typically owned by the managing therapist, directly or indirectly, are recorded within the balance sheets and income statements as non-controlling interests.

Wholly-Owned Facilities

For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due to the profit sharing therapists. The amount is expensed as compensation and included in clinic operating costs – salaries and related costs. The respective liability is included in current liabilities – accrued expenses on the balance sheet.

Significant Accounting Policies

Long-Lived Assets

Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the related assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the related lease term or estimated useful lives of the assets, which is generally three to five years.

Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the related amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Goodwill

Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital.

The fair value of goodwill and other intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining our reporting units when performing our annual goodwill impairment test.

An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2012, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation in the third quarter of 2012 did not yield any impairment charge.

Non-controlling interests

The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the income statement. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling interest on the deconsolidation date.

8

When the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.

Revenue Recognition

Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.

The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.

Medicare Reimbursement

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (“MPFS”). The MPFS rates are automatically updated annually based on a formula, called the sustainable growth rate (“SGR”) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through 2013, Centers for Medicare & Medicaid Services (“CMS”) or Congress has taken action to prevent the implementation of SGR formula reductions. For 2012, the Temporary Payroll Tax Cut Continuation Act of 2011 (“TPTC”) delayed application of the SGR for the first two months of the year and the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”) included a measure freezing payment rates at their then current level through December 31, 2012. The American Taxpayer Relief Act of 2012 essentially froze the Medicare physician fee schedule rates at 2012 levels through December 31, 2013, averting a scheduled 26.5% cut as a result of the SGR formula that would have taken effect on January 1, 2013. A reduction in the Medicare physician fee schedule payment rates will occur on January 1, 2014, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.

The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. The American Taxpayer Relief Act of 2012 temporarily delayed the automatic, across-the-board “sequestration” cuts in federal spending imposed by the Budget Control Act of 2011. Effective April 1, 2013, Medicare reimbursement for services furnished on or after April 1, 2013 has been reduced by 2%. The MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. As of July 1, 2013, therapists are required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. For claims submitted after July 1, 2013, CMS will reject claims if the required data is not included in the claim.

As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the “Therapy Cap” or “Limit”) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy. During 2012, the annual Limit on outpatient therapy services was $1,880 for Physical Therapy and Speech Language Pathology Services combined and $1,880 for Occupational Therapy Services. Pursuant to the final MPFS rule for 2013, effective January 1, 2013 the annual Limit on outpatient therapy services is $1,900 for Physical Therapy and Speech Language Pathology Services combined and $1,900 for Occupational Therapy Services. Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the American Taxpayer Relief Act of 2012 extended the annual limits on therapy expenses to services furnished in hospital outpatient department settings from October 1, 2012 through December 31, 2013. Unless Congress enacts legislation to extend the application of these limits to therapy provided in hospital outpatient settings, the Therapy Cap will no longer apply to such services starting as of January 1, 2014.

9

In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses. Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) is able to request an exception from the Therapy Caps if the provision of therapy services was deemed to be medically necessary. Therapy Cap exceptions have been available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity. The MCTRA extended the exceptions process for outpatient Therapy Caps through December 31, 2012. The American Taxpayer Relief Act of 2012 extended the exceptions process for outpatient Therapy Caps through December 31, 2013. Unless Congress extends the exceptions process, the Therapy Caps will apply to all outpatient therapy services beginning January 1, 2014, except those services furnished and billed by outpatient hospital departments.

Furthermore, under the MCTRA, since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review prior to payment. The $3,700 threshold is applied to the combined physical therapy/speech language pathology cap; a separate $3,700 threshold is applied to the occupational therapy cap. The American Taxpayer Relief Act of 2012 extended through December 31, 2013 the requirement that Medicare perform manual medical review of therapy services beyond the $3,700 threshold and continued the process by which providers may seek pre-approval for services to be performed beyond such dollar threshold. In February 2013, CMS advised providers that the pre-approval process for services beyond the $3,700 cap will no longer be in effect, so that all such services during the calendar year that are over the dollar threshold will be subject to a manual medical review.

CMS adopted a multiple procedure payment reduction (“MPPR”) for therapy services in the final update to the MPFS for calendar year 2011. During 2011, the MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (“RVU”) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increased the payment reduction to 50%, on subsequent therapy procedures in either setting, effective April 1, 2013. This reduction in payment for our services provided to Medicare beneficiaries will negatively impact the Company’s financial results, estimated to represent an 8% to 10% reduction in overall reimbursement for services the Company provides to Medicare beneficiaries.

Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of June 30, 2013. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program.

Physician Services Revenues

Revenues from physician services are generated by franchise arrangements and fees from third parties, pursuant to which there are multiple deliverables — training and ongoing services — as well as through the one physician services facility which is scheduled to close in August 2013. Each component can be purchased separately. Revenue is recognized over the period the respective services are provided. Physician service revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.

Management Contract Revenues

Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.

10

Contractual Allowances

Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements for such services by both insurance companies and government sponsored healthcare programs. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow it to provide the necessary detail and accuracy with its collectibility estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing systems may not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, the difference between net revenues and corresponding cash collections has historically generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis shows a less than 1% difference between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at June 30, 2013.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Company recognizes accrued interest expense and penalties associated with unrecognized tax benefits as income tax expense. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the three and six months ended June 30, 2013 and 2012.

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount of the Company’s revolving line of credit approximates its fair value. The interest rate on the revolving line of credit, which is tied to the Eurodollar Rate, is set at various short-term intervals as detailed in the credit agreement.

Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.

11

Use of Estimates

In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.

Self-Insurance Program

The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through June 30, 2013.

Restricted Stock

Restricted stock issued to employees and directors is subject to certain conditions, including continued employment or continued service on our Board of Directors (the “Board”), respectively. The transfer restrictions for shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the service period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.

2. EARNINGS PER SHARE

The computations of basic and diluted earnings per share for the Company are as follows (in thousands, except per share data):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Numerator:
Net income attributable to common shareholders	$	4,914	$	4,849	$	8,635	$	9,327
Denominator:
Denominator for basic earnings per share - weighted-average shares		12,089		11,781		12,022		11,754
Effect of dilutive securities - Stock options		21		122		22		118
Denominator for diluted earnings per share - adjusted weighted-average shares		12,110		11,903		12,044		11,872
Earnings per share attributable to common shareholders:
Basic	$	0.41	$	0.41	$	0.72	$	0.79
Diluted	$	0.41	$	0.41	$	0.72	$	0.79

All options to purchase shares were included in the diluted earnings per share calculation for the three and six months ended June 30, 2013 and 2012 as the average market prices of the common stock was above the exercise prices. The Company’s restricted stock issued is included in basic and diluted shares for the earnings per share computation from the date of grant.

12

3. ACQUISITIONS OF BUSINESSES

The purchase price for the 72% interest in the February 2013 Acquisition was $4.3 million in cash and $400,000 in a seller note, that is payable in two principal installments totaling $200,000 each, plus accrued interest, in February 2014 and 2015. The purchase price for the 50% interest in the April 2013 Acquisition was $2.4 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in April of 2014 and 2015. The purchase price for the 80% interest in the May 2013 Acquisition was $3.6 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in May of 2014 and 2015. On February 1, 2013, through a subsidiary, the Company acquired a 100% interest in a clinic for $5,000 and on June 1, 2013, through another subsidiary, the Company acquired a 100% interest in a clinic for $95,000. The purchase prices have been preliminarily allocated as follows (in thousands):

Cash paid, net of cash acquired	$	9,998
Seller notes		800
Total consideration	$	10,798
Estimated fair value of net tangible assets acquired:
Total current assets	$	1,349
Total non-current assets		719
Total liabilities		(242	)
Net tangible assets acquired		1,826
Goodwill		14,400
Fair value of noncontrolling interest		(5,428	)
	$	10,798

The consideration for each transaction was agreed upon through arm’s length negotiations. Funding for the cash portion of the purchase price was derived from proceeds from the Company’s revolving credit facility.

The results of operations of these acquisitions have been included in the Company’s consolidated financial statements since acquired.

Because these acquisitions occurred during the six months ended June 30, 2013, the purchase price plus the fair value of the non-controlling interest was allocated to the fair value of the assets acquired and liabilities assumed based on the preliminary estimates of the fair values at the acquisition date, with the amount exceeding the estimated fair values being recorded as goodwill. The Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used at June 30, 2013 based on additional information obtained. Changes in the estimated valuation of the tangible and intangible assets acquired and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill.

On May 22, 2012, the Company purchased a 70% interest in a 7 clinic group (“May 2012 Acquisition”). The purchase price for the 70% interest in the May 2012 Acquisition was $6,090,000 in cash and $250,000 in seller notes, that are payable in two principal installments totaling $125,000 each, plus any accrued interest, in May 2013 and 2014. The seller notes accrue interest at 3.25% per annum. For the Company, 70% of the goodwill for the May 2012 Acquisition is tax deductible. During the quarter ended March 31, 2013, the Company determined that the amounts attributable to intangible assets other than goodwill are as follows: tradenames - $1,300,000; referral relationships - $800,000; and non competition agreement - $240,000. The value assigned to referral relationships and the non competion agreements will be amortized over the related expected lives which are estimated to be 12 and six years, respectively.

13

In addition to the May 2012 Acquisition, in 2012, the Company, through its subsidiaries, purchased 7 outpatient therapy practices in 7 transactions for aggregate cash consideration of $1,938,000 and, in one transaction, a $100,000 note payable. The purchase prices were allocated $43,000 to current assets, $213,000 to non-current assets, $25,000 to non competition agreements, $57,000 to referral relationships and $1,883,000 to goodwill.

The purchase prices for the acquisitions in 2012 have been allocated as follows (in thousands):

Cash paid, net of cash acquired	$	7,929
Seller notes		350
Total consideration	$	8,279
Estimated fair value of net tangible assets acquired:
Total current assets	$	363
Total non-current assets		478
Total liabilities		(290	)
Net tangible assets acquired	$	551
Tradenames		1,300
Referral relationships		857
Non competition agreements		265
Goodwill		8,198
Fair value of noncontrolling interest		(2,892	)
	$	8,279

The purchase price plus the fair value of the non-controlling interest for the 2012 acquisitions was allocated to the fair value of the assets acquired and liabilities assumed based on the fair values at the acquisition date, with the amount exceeding the fair values being recorded as goodwill.

Unaudited proforma consolidated financial information for acquisitions occurring in 2013 and 2012 have not been included as the results were not material to current operations.

4. ACQUISITIONS OF NON-CONTROLLING INTERESTS

In six separate transactions during the six months ended June 30, 2013, the Company purchased partnership interests in five partnerships. The interests in the partnerships purchased ranged from .1% to 35%. The aggregate of the purchase prices paid was $1.2 million, which included $97,000 of undistributed earnings. The remaining purchase price of $1.1 million, less future tax benefits of $415,000, was recognized as an adjustment to additional paid-in capital. For one of the transactions, the non-controlling interest had a $37,000 cumulative loss. This loss less the tax benefit of $14,000 was charged to additional paid-in capital. During the six months ended June 30, 2013, the Company sold a 1% interest in two separate partnerships for an aggregate price of $112,000. This amount, less tax effect of $34,000, was credited to additional paid-in capital.

Included in the above purchases of partnership interests, the Company purchased the remaining 1.3% of the non-controlling interest in STAR Physical Therapy, LP, a subsidiary of the Company (“STAR”) held by Mr. Regg Swanson, the Managing Director and a founder of STAR and a member of the Board (“Swanson”). The purchase price paid for the 1.3% interest was $801,640, which included $55,000 of undistributed earnings. The purchase price was determined based on the contractual terms in the Reorganization of Securities Purchase Agreement dated as of September 6, 2007 among the Company, STAR, the limited partners of STAR and Swanson as Seller Representative and in his individual capacity, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 7, 2007. After this transaction, Swanson does not hold any interest in STAR.

14

5. GOODWILL

The changes in the carrying amount of goodwill consisted of the following (in thousands):

	Six Months Ended June 30, 2013
Beginning balance	$	100,188
Goodwill acquired during the period		14,400
Goodwill allocated to specific assets for business acquired in 2012		(2,340	)
Ending balance	$	112,248

6. INTANGIBLE ASSETS, NET

Intangible assets, net as of June 30, 2013 and December 31, 2012 consisted of the following (in thousands):

	June 30,		December 31,
	2013		2012
Tradenames	$	9,273	$	7,973
Referral relationships, net of accumulated amortization of $1,483 and $1,217, respectively		4,035		3,501
Non compete agreements, net of accumulated amortization of $2,039 and $1,848, respectively		721		672
	$	14,029	$	12,146

Tradenames, referral relationships and non competition agreements are related to the businesses acquired. The value assigned to tradenames has an indefinite life and is tested at least annually for impairment in conjunction with the Company’s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non competitionagreements are amortized over the respective term of the agreements which range from five to six years.

15

The following table details the amount of amortization expense recorded for intangible assets for the three and six months ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Referral relationships	$	116	$	100	$	266	$	178
Non compete agreements		85		112		191		203
	$	201	$	212	$	457	$	381

Based on the balance of referral relationships and non competition agreements as of June 30, 2013, the expected amount to be amortized in 2013 and thereafter by year is as follows (in thousands):

Referral Relationships			Non Compete Agreements
	Annual			Annual
Years	Amount		Years	Amount
2013		498	2013		341
2014		462	2014		180
2015		441	2015		180
2016		441	2016		118
2017		441	2017		73
2018		405	2018		20
2019		368
2020		361
2021		336
2022		288
2023		180
2024		80

7. NOTES PAYABLE AND CREDIT AGREEMENT

Credit Agreement and notes payable as of June 30, 2013 and December 31, 2012 consisted of the following ($ in thousands):

	2013			2012
Credit Agreement average effective interest rate of 3.0% inclusive of unused fee	$	15,750		$	17,400
Various notes payable with $800 plus accrued interest due in the next year interest accrues at 3.25% per annum		1,200			634
		16,950			18,034
Less current portion		(800	)		(459	)
	$	16,150		$	17,575

16

Effective August 27, 2007, the Company entered into a credit agreement with a commitment for a $30.0 million revolving credit facility which was increased to $50.0 million effective June 4, 2008 and increased to $75.0 million effective July 14, 2011 (the “Credit Agreement”). Effective March 18, 2009, the Credit Agreement was amended to permit the purchase up to $15,000,000 of the Company’s common stock subject to compliance with certain covenants, including the requirement that after giving effect to any stock purchase, the Company’s consolidated leverage ratio (as defined in the Credit Agreement) be less than 1.0 to 1.0 and that any stock repurchased be retired within seven days of purchase. Effective October 13, 2010, the Credit Agreement was amended to extend the maturity date from August 31, 2011 to August 31, 2015. In addition, the Credit Agreement was amended to adjust the pricing grid which is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.6% to 2.5% or the applicable spread over the Base Rate ranging from .1% to 1%. Effective October 24, 2012, the Credit Agreement was amended to permit the Company to purchase, commencing on October 24, 2012, and at all times thereafter, up to $15,000,000 of its common stock subject to compliance with covenants. On December 3, 2012, the Credit Agreement was amended to allow the Company to pay a special dividend of $0.40 per share. The Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common shareholders, capital expenditures and other corporate purposes. Fees under the Credit Agreement include an unused commitment fee ranging from .1% to .25% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement. On June 30, 2013, $15.8 million was outstanding under the Credit Agreement resulting in $59.2 million of availability. As of June 30, 2013, the Company was in compliance with all of the covenants thereunder.

The Company generally enters into various notes payable as a means of financing a portion of its acquisitions and purchases of non-controlling interests. In conjunction with the clinic group acquisitions, the Company entered into several seller notes. See Note 3 to consolidated financial statements – Acquisitions of Businesses.

Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to June 30, 2013 are as follows (in thousands):

During the twelve months ended June 30, 2014	$	800
During the twelve months ended June 30, 2015	$	400
During the twelve months ended June 30, 2016	$	15,750
	$	16,950

8. COMMON STOCK

From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company’s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, the Company amended the Credit Agreement to permit share repurchases of up to $15,000,000. The Company is required to retire shares purchased under the March 2009 Authorization.

Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. The Credit Agreement was further amended to permit the Company to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of its common stock subject to compliance with covenants. There are currently an additional estimated 340,501 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company’s cash position. The Company did not purchase any shares of its common stock during the three months and six months ended June 30, 2013.

17

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

EXECUTIVE SUMMARY

Our Business

We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. As of June 30, 2013, we operated 449 clinics in 43 states, including one physician services facility.

We also manage physical therapy facilities for third parties, primarily physicians, with 17 third-party facilities under management as of June 30, 2013.

We also derived revenues from physician services which are generated by franchise arrangements and fees with third parties and through one physician services facility. The franchise arrangements contain multiple deliverables - training and ongoing services. Each component can be purchased separately.

In November 2007, we formed a new venture, OsteoArthritis Centers of America, LP (“OA Centers”), and initially opened two locations. The business specializes in the outpatient, non-surgical treatment of osteo arthritis, degenerative joint disease and other musculoskeletal conditions. In October 2008, we acquired a 65% interest in Rehab Management Group (“RMG”). RMG provides physicians and their patients with clinical services including electro-diagnostic analysis (“EDX”) as well as intra articular joint (“IAJP Direct”) and lumbar osteoarthritis (“LOP Direct”) programs. The operations of OA Centers and RMG are referred to as our “Physician Services Business”.

In 2012, and through the first six months of 2013, the margin from the Physician Services Business was negative. See Gross Margin discussions below.

In the first quarter of 2013, we made a management change to oversee the Physician Services Business. In December 2012, we closed one of the OA Centers and will close the second location in late August 2013. We expect to incur approximately $50,000 in cost in August 2013 related to the OA Center closure. In the event that we are unsuccessful in returning the RMG part of the Physician Services Business to former levels of profitability, we may be required to write-down a portion of or all of the goodwill and other intangible assets associated with RMG. As of June 30, 2013, the goodwill and other intangible assets of RMG were valued at $6.4 million.

During the six months ended June 30, 2013, we acquired the following physical therapy clinic groups:

Acquisition	Date	% Interest Acquired			Number of Clinics
February 2013 Acquisition	Feb 28		72	%		9
April 2013 Acquisition	Apr 30		50	%		5
May 2013 Acquisition	May 24		80	%		5

In addition to the above clinic groups, we acquired, through two of our subsidiaries, two physical therapy clinics in two separate transactions during the six months ended June 30, 2013 - one in February and one in June (the “Tuck-In Acquisitions).

The results of operations of the acquired clinics have been included in our consolidated financial statements since the date of their acquisition.

18

Selected Operating and Financial Data

The following table presents selected operating and financial data that we believe are key indicators of our operating performance.

	For the Three Months				For the Six Months
	Ended June 30,				Ended June 30,
	2013		2012		2013		2012
Number of clinics, at the end of period		449		419		449		419
Working days		64		64		127		128
Average visits per day per clinic		21.6		22.1		21.3		21.9
Total patient visits		614,241		587,324		1,192,116		1,165,994
Net patient revenue per visit	$	106.30	$	105.65	$	106.37	$	105.10

RESULTS OF OPERATIONS

Three Months Ended June 30, 2013 Compared to the Three Months Ended June 30, 2012

• Net revenues increased to $67.2 million for the three months ended June 30, 2013 (“2013 Second Quarter”) from $64.0 million for the three months ended June 30, 2012 (“2012 Second Quarter”) primarily due to an increase in visits of 27,000 from 587,000 for the 2012 Second Quarter to 614,000 for the 2013 Second Quarter and an increase in the average net patient revenue per visit for the 2013 Second Quarter to $106.30 from $105.65 in the 2012 Second Quarter.

• Net income attributable to our common shareholders for the 2013 Second Quarter was $4.9 million versus $4.8 million for the 2012 Second Quarter. Net income was $0.41 per diluted share for both periods. Total diluted shares were 12.1 million for the 2013 Second Quarter and 11.9 million for the 2012 Second Quarter.

Net Patient Revenues

• Net patient revenues increased to $65.3 million for the 2013 Second Quarter from $62.1 million for the 2012 Second Quarter, an increase of $3.2 million, or 5.2%, due to an increase in visits, due to clinics opened and acquired between July 1, 2012 and June 30, 2013 (“New Clinics”), and an increase in the net patient revenue per visit of $0.65.

• Net patient revenues related to New Clinics amounted to $3.6 million for the 2013 Second Quarter and net patient revenues for clinics opened or acquired prior to July 1, 2012 (“Mature Clinics”) decreased by $0.4 million for the 2013 Second Quarter as compared to the 2012 Second Quarter. Patient visits for Mature Clinics in the 2013 Second Quarter were 6,400 less than in the 2012 Second Quarter.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

Other Revenues

Other revenues remained relatively the same for both periods.

19

Clinic Operating Costs

Clinic operating costs as a percentage of net revenues were 74.3% for the 2013 Second Quarter and 73.4% for the 2012 Second Quarter.

Clinic Operating Costs - Salaries and Related Costs

Salaries and related costs increased to $35.8 million for the 2013 Second Quarter from $32.7 million for the 2012 Second Quarter, an increase of $3.1 million, or 9.6%. Salaries and related costs for New Clinics amounted to $2.3 million for the 2013 Second Quarter. Salaries and related costs for Mature Clinics increased by $0.8 million for the 2013 Second Quarter as compared to the 2012 Second Quarter. The increase in salaries and related costs for Mature Clinics is due to the results of the acquisition of a 7 clinic group in May of 2012 (“May 2012 Acquisition). The 2013 Second Quarter includes three months of activity, and the 2012 Second Quarter includes slightly over one month of activity, for the May 2012 Acquisition. Salaries and related costs as a percentage of net revenues were 53.3% for the 2013 Second Quarter and 51.1% for the 2012 Second Quarter.

Clinic Operating Costs - Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $12.9 million for the 2013 Second Quarter and $13.0 million for the 2012 Second Quarter. For New Clinics, rent, clinic supplies, contract labor and other amounted to $0.9 million for the 2013 Second Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other decreased by $1.0 million in the 2013 Second Quarter compared to the 2012 Second Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 19.2% for the 2013 Second Quarter and 20.3% for the 2012 Second Quarter.

Clinic Operating Costs - Provision for Doubtful Accounts

The provision for doubtful accounts was $1.2 million for the 2013 Second Quarter and $1.3 million for the 2012 Second Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.8% for the 2013 Second Quarter and 2.1% for the 2012 Second Quarter.

Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.1% at June 30, 2013, as compared to 5.8% at December 31, 2012. Our days sales outstanding was 40 days at June 30, 2013 and 42 days at December 31, 2012.

Gross Margin

The following table details the gross margin derived from our core physical therapy business and physician services business for the 2013 Second Quarter and 2012 Second Quarter (in thousands):

	Three Months Ended June 30,
	2013			2012
Gross margin - physical therapy services	$	17,586		$	17,140
Gross margin - physician services		(280	)		(146	)
Gross margin	$	17,306		$	16,994

In the first quarter of 2013, we made a management change to oversee the Physician Services Business. In December 2012, we closed one of the OA Centers and will close the second location in late August 2013. We expect to incur approximately $50,000 in cost in August 2013 related to the OA Center closure. In the event that we are unsuccessful in returning the RMG part of the Physician Services Business to former levels of profitability, the Company may be required to write-down a portion of or all of the goodwill and other intangible assets associated with RMG. As of June 30, 2013, the goodwill and other intangible assets of RMG were valued at $6.4 million.

Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, professional, and recruiting fees, were $6.6 million for the 2013 Second Quarter and $6.4 million for the 2012 Second Quarter. As a percentage of net revenues, corporate office costs were 9.9% for the 2013 Second Quarter and 10.0% for the 2012 Second Quarter.

20

Interest Expense

Interest expense decreased to $130,000 in the 2013 Second Quarter compared to $145,000 in the 2012 Second Quarter due to a lower average outstanding balance under the Credit Agreement during the 2013 period compared to the 2012 period. At June 30, 2013, $15,750,000 was outstanding under our Credit Agreement.

Provision for Income Taxes

The provision for income taxes was $3.2 million for the 2013 Second Quarter and $3.1 million for the 2012 Second Quarter. During the 2013 and 2012 Second Quarters, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 39.3%.

Non-controlling Interests

Net income attributable to non-controlling interests was $2.5 million for the 2013 Second Quarter and for the 2012 Second Quarter. Net income attributable to non-controlling interests as a percentage of operating income before corporate office costs was 14.2% for the 2013 Second Quarter and 14.5% for the 2012 Second Quarter.

Six Months Ended June 30, 2013 Compared to the Six Months Ended June 30, 2012

• Net revenues increased to $130.3 million for the Six Months ended June 30, 2013 (“2013 First Six Months”) from $126.5 million for the Six Months ended June 30, 2012 (“2012 First Six Months”) primarily due to an increase in visits of 26,000 from 1,166,000 for the 2012 First Six Months to 1,192,000 for the 2013 First Six Months and an increase in the average net patient revenue per visit for the 2013 First Six Months to $106.37 from $105.10 in the 2012 First Six Months.

• Net income attributable to our common shareholders for the 2013 First Six Months was $8.6 million versus $9.3 million for the 2012 First Six Months. Net income was $0.72 per diluted share for the 2013 First Six Months compared to $0.79 for the 2012 First Six Months. Total diluted shares were 12.0 million for the 2013 First Six Months and 11.9 million for the 2012 First Six Months.

Net Patient Revenues

• Net patient revenues increased to $126.8 million for the 2013 First Six Months from $122.6 million for the 2012 First Six Months, an increase of $4.2 million, or 3.5%, due to an increase in visits, due to New Clinics, and an increase in the net patient revenue per visit of $1.27.

• Net patient revenues related to New Clinics amounted to $5.1 million for the 2013 First Six Months and net patient revenues for Mature Clinics decreased by $0.9 million for the 2013 First Six Months as compared to the 2012 First Six Months. Patient visits for Mature Clinics in the 2013 First Six Months were 20,800 less than in the 2012 First Six Months.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

Other Revenues

Other revenues were $3.5 million for the 2013 First Six Months compared to $4.0 million for the 2012 First Six Months. The decrease of $0.5 million was due to reduced revenues in the RMG part of the Physician Services Business. See Gross Margin discussion below.

21

Clinic Operating Costs

Clinic operating costs as a percentage of net revenues were 75.5% for the 2013 First Six Months and 73.8% for the 2012 First Six Months.

Clinic Operating Costs - Salaries and Related Costs

Salaries and related costs increased to $70.2 million for the 2013 First Six Months from $65.5 million for the 2012 First Six Months, an increase of $4.7 million, or 7.3%. Salaries and related costs for New Clinics amounted to $3.4 million for the 2013 First Six Months. Salaries and related costs for Mature Clinics increased by $1.4 million for the 2013 First Six Months as compared to the 2012 First Six Months. The increase in salaries and related costs for Mature Clinics is due to the results of the May 2012 Acquisition. The 2013 First Six Months includes six months of activity, and the 2012 First Six Months includes slightly over one month of activity, for the May 2012 Acquisition. Salaries and related costs as a percentage of net revenues were 53.9% for the 2013 First Six Months and 51.7% for the 2012 First Six Months.

Clinic Operating Costs - Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $25.8 million for the 2013 First Six Months and $25.5 million for the 2012 First Six Months. For New Clinics, rent, clinic supplies, contract labor and other amounted to $1.4 million for the 2013 First Six Months. For Mature Clinics, rent, clinic supplies, contract labor and other decreased by $1.1 million in the 2013 First Six Months compared to the 2012 First Six Months. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 19.8% for the 2013 First Six Months and 20.1% for the 2012 First Six Months.

Clinic Operating Costs - Provision for Doubtful Accounts

The provision for doubtful accounts was $2.3 million for the 2013 First Six Months and $2.4 million for the 2012 First Six Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.8% for the 2013 First Six Months and 2.0% for the 2012 First Six Months.

Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.1% at June 30, 2013, as compared to 5.8% at December 31, 2012. Our days sales outstanding was 40 days at June 30, 2013 and 42 days at December 31, 2012.

Gross Margin

The following table details the gross margin derived from our core physical therapy business and physician services business for the 2013 First Six Months and 2012 First Six Months (in thousands):

	Six Months Ended June 30,
	2013			2012
Gross margin - physical therapy services	$	32,437		$	33,106
Gross margin - physician services		(473	)		21
Gross margin	$	31,964		$	33,127

In the first quarter of 2013, we made a management change to oversee the Physician Services Business. In December 2012, we closed one of the OA Centers and will close the second location in late August 2013. We expect to incur approximately $50,000 in cost in August 2013 related to the OA Center closure. In the event that we are unsuccessful in returning the RMG part of the Physician Services Business to former levels of profitability, we may be required to write-down a portion of or all of the goodwill and other intangible assets associated with RMG. As of June 30, 2013, the goodwill and other intangible assets of RMG were valued at $6.4 million.

Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, professional, and recruiting fees, were $13.1 million for the 2013 First Six Months and $12.7 million for the 2012 First Six Months. As a percentage of net revenues, corporate office costs were 10.1% for the 2013 First Six Months and 10.0% for the 2012 First Six Months.

22

Interest Expense

Interest expense decreased to $265,000 in the 2013 First Six Months compared to $307,000 in the 2012 First Six Months due to a lower average outstanding balance under our Credit Agreement during the 2013 period compared to the 2012 period. At June 30, 2013, $15,750,000 was outstanding under our Credit Agreement.

Provision for Income Taxes

The provision for income taxes was $5.6 million for the 2013 First Six Months and $6.0 million for the 2012 First Six Months. During the 2013 and 2012 First Six Months, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 39.3%.

Non-controlling Interests

Net income attributable to non-controlling interests was $4.3 million for the 2013 First Six Months and $4.8 million for the 2012 First Six Months. Net income attributable to non-controlling interests as a percentage of operating income before corporate office costs was 13.6% for the 2013 First Six Months and 14.5% for the 2012 First Six Months. The decrease in the percentage is primarily due to the purchases of non-controlling interests in various partnerships during 2012 and 2013. During 2012, we purchased partnership interests in 15 separate partnerships which interest ranged from 10% to 35% and during the 2013 First Six Months, we purchased partnership interests in five separate partnerships which interest ranged from .1% to 35%.

LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At June 30, 2013, we had $10.3 million in cash compared to cash of $11.7 million at December 31, 2012. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our $75.0 million Credit Agreement are sufficient to fund the working capital needs of our operating subsidiaries, corporate costs, dividends, purchases of our common stock, accrued clinic closure costs, future clinic development and investments through at least June 2014. Significant acquisitions of clinics and/or non-controlling interests would likely require financing under our Credit Agreement.

During the 2013 First Six Months, $20.7 million was provided by operations. The major uses of cash included: purchasees of businesses ($10.0 million), distributions to non-controlling interest partners ($4.4 million), purchases of fixed assets ($2.4 million), payments of cash dividends to our shareholders ($2.4 million), net pay down on our Credit Agreement ($1.7 million) and payments for acquisitions of non-controlling interests ($1.1 million).

Effective August 27, 2007, we entered into a credit agreement with a commitment for a $30.0 million revolving credit facility which was increased to $50.0 million effective June 4, 2008 and increased to $75.0 million effective July 14, 2011 (the “Credit Agreement”). Effective March 18, 2009, we amended the Credit Agreement to permit us to purchase up to $15,000,000 of our common stock subject to compliance with certain covenants, including the requirement that after giving effect to any stock purchase, our consolidated leverage ratio (as defined in the Credit Agreement) be less than 1.0 to 1.0 and that any stock repurchased be retired within seven days of purchase. Effective October 13, 2010, we amended the Credit Agreement to extend the maturity date from August 31, 2011 to August 31, 2015. In addition, the Credit Agreement was amended to adjust the pricing grid which is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.6% to 2.5% or the applicable spread over the Base Rate ranging from .1% to 1%. Effective October 24, 2012, we amended the Credit Agreement to permit us to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of our common stock subject to compliance with covenants. On December 3, 2012, we amended the Credit to allow the Company to pay a special dividend of $0.40 per share. The Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. The Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common shareholders, capital expenditures and other corporate purposes. Fees under the Credit Agreement include an unused commitment fee ranging from .1% to .25% depending on our consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement. On June 30, 2013, $15.8 million was outstanding under the Credit Agreement resulting in $59.2 million of availability, and we were in compliance with all of the covenants thereunder.

23

Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.

We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.

We generally enter into various notes payable as a means of financing a portion of the purchase price of our acquisitions. Our presently outstanding notes payable relate to acquisitions that occurred in 2013, 2012 and 2011. At June 30, 2013, the balance on these notes payable was $1,200,000.

In conjunction with acquisitions that occurred in 2010 through 2013, in the event that a limited minority partner’s employment ceases at any time after three years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.

From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, we amended our bank credit agreement to permit share repurchases of up to $15,000,000. We are required to retire shares purchased under the March 2009 Authorization. Effective October 24, 2012, we amended the Credit Agreement to permit us to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of our common stock subject to compliance with covenants.

There is no expiration date for the share repurchase program. As of June 30, 2013, there are currently an additional estimated 341,000 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the six months ended June 30, 2013.

FACTORS AFFECTING FUTURE RESULTS

The risks related to our business and operations include:

• The uncertain economic conditions and the historically high unemployment rate in the United States may have material adverse impacts on our business and financial condition that we currently cannot predict.

• We depend upon reimbursement by third-party payors including Medicare and Medicaid.

• Changes as a result of healthcare reform legislation, and implementation thereof, may affect our business.

• We depend upon the cultivation and maintenance of relationships with the physicians in our markets.

• We also depend upon our ability to recruit and retain experienced physical and occupational therapists.

• Our revenues may fluctuate due to weather.

• Our operations are subject to extensive regulation.

• We operate in a highly competitive industry.

• We may incur closure costs and losses.

• Future acquisitions may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.

• Certain of our internal controls, particularly as they relate to billings and cash collections, are largely decentralized at our clinic locations.

See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012.

24

Forward-Looking Statements

We make statements in this report that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934. These statements contain forward-looking information relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

• changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status,

• revenue and earnings expectations;

• general economic conditions;

• business and regulatory conditions including federal and state regulations;

• changes as the result of government enacted national healthcare reform;

• availability and cost of qualified physical and occupational therapists;

• personnel productivity;

• competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;

• changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;

• maintaining adequate internal controls;

• availability, terms, and use of capital;

• acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses; and

• weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Credit Agreement. The interest on our Credit Agreement is based on a variable rate. At June 30, 2013, $15.8 million was outstanding under our Credit Agreement. Based on the balance of the Credit Agreement at June 30, 2013, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $157,500.

25

ITEM 4. CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 6. EXHIBITS.

Exhibit Number	Description
10.1	U. S. Physical Therapy, Inc. Long-Term Incentive Plan for Senior Management for 2013, effective March 27, 2013 (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2013).
10.2	U. S. Physical Therapy, Inc. Objective Cash Bonus Plan for 2013, effective March 27, 2013 (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2013).
10.3	U. S. Physical Therapy, Inc. Discretionary Cash Bonus Plan for 2013, effective March 27, 2013 (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2013).
31.1*	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
31.2*	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
31.3*	Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller.
32*	Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith

26

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.

	U.S. PHYSICAL THERAPY, INC.
Date: August 8, 2013	By:	/s/ LAWRANCE W. MCAFEE
		Lawrance W. McAfee
		Chief Financial Officer
		(duly authorized officer and principal financial and accounting officer)
	By:	/s/ JON C. BATES
		Jon C. Bates
		Vice President/Corporate Controller

27

INDEX OF EXHIBITS

Exhibit Number	Description
10.1	U. S. Physical Therapy, Inc. Long-Term Incentive Plan for Senior Management for 2013, effective March 27, 2013 (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2013).
10.2	U. S. Physical Therapy, Inc. Objective Cash Bonus Plan for 2013, effective March 27, 2013 (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2013).
10.3	U. S. Physical Therapy, Inc. Discretionary Cash Bonus Plan for 2013, effective March 27, 2013 (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2013).
31.1*	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
31.2*	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
31.3*	Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller.
32*	Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith

28

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Christopher Reading, certify that:

1. I have reviewed this quarterly report on Form 10-Q of U.S. Physical Therapy, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ CHRISTOPHER READING

Christopher Reading

President and Chief Executive Officer

(principal executive officer)

Date: August 8, 2013

29

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Lawrance W. McAfee, certify that:

1. I have reviewed this quarterly report on Form 10-Q of U.S. Physical Therapy, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ LAWRANCE W. MCAFEE

Lawrance W. McAfee

Chief Financial Officer

(principal financial and accounting officer)

Date: August 8, 2013

30

EX-31.3

EXHIBIT 31.3

CERTIFICATION

I, Jon C. Bates, certify that:

1. I have reviewed this quarterly report on Form 10-Q of U.S. Physical Therapy, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ JON C. BATES

Jon C. Bates

Vice President/Corporate Controller

Date: August 8, 2013

31

EX-32

EXHIBIT 32

CERTIFICATION OF PERIODIC REPORT

In connection with the Quarterly Report of U.S. Physical Therapy, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher J. Reading, President and Chief Executive Officer of the Company, Lawrance W. McAfee, Chief Financial Officer of the Company, and Jon C. Bates, Vice President and Corporate Controller of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 8, 2013

/s/ CHRISTOPHER J. READING

Christopher J. Reading

Chief Executive Officer

/s/ LAWRANCE W. MCAFEE

Lawrance W. McAfee

Chief Financial Officer

/s/ JON C. BATES

Jon C. Bates

Vice President/Corporate Controller

This certification is made solely pursuant to the requirement of Section 1350 of 18 U.S.C., and is not for any other purpose. A signed original of this written statement required by Section 906 has been provided to U. S. Physical Therapy, Inc. and will be retained by U. S. Physical Therapy, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

32

XML

EARNINGS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share for the Company are as follows (in thousands, except per share data):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Numerator:
Net income attributable to common shareholders	$	4,914	$	4,849	$	8,635	$	9,327
Denominator:
Denominator for basic earnings per share - weighted-average shares		12,089		11,781		12,022		11,754
Effect of dilutive securities - Stock options		21		122		22		118
Denominator for diluted earnings per share - adjusted weighted-average shares		12,110		11,903		12,044		11,872
Earnings per share attributable to common shareholders:
Basic	$	0.41	$	0.41	$	0.72	$	0.79
Diluted	$	0.41	$	0.41	$	0.72	$	0.79

XML

CONSOLIDATED STATEMENTS OF NET INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Statement [Abstract]
Net patient revenues	$ 65,295	$ 62,052	$ 126,800	$ 122,551
Other revenues	1,929	1,907	3,522	3,990
Net revenues	67,224	63,959	130,322	126,541
Clinic operating costs:
Salaries and related costs	35,813	32,671	70,228	65,470
Rent, clinic supplies, contract labor and other	12,904	12,992	25,822	25,476
Provision for doubtful accounts	1,193	1,280	2,282	2,397
Closure costs	8	22	26	71
Total clinic operating costs	49,918	46,965	98,358	93,414
Gross margin	17,306	16,994	31,964	33,127
Corporate office costs	6,622	6,396	13,129	12,658
Operating income	10,684	10,598	18,835	20,469
Interest and other income, net	1	1	3	3
Interest expense	(130)	(145)	(265)	(307)
Income before taxes	10,555	10,454	18,573	20,165
Provision for income taxes	3,181	3,140	5,590	6,039
Net income including noncontrolling interests	7,374	7,314	12,983	14,126
Less: net income attributable to noncontrolling interests	(2,460)	(2,465)	(4,348)	(4,799)
Net income attributable to common shareholders	$ 4,914	$ 4,849	$ 8,635	$ 9,327
Earnings per share attributable to common shareholders:
Basic	$ 0.41	$ 0.41	$ 0.72	$ 0.79
Diluted	$ 0.41	$ 0.41	$ 0.72	$ 0.79
Shares used in computation:
Basic	12,089	11,781	12,022	11,754
Diluted	12,110	11,903	12,044	11,872
Dividends declared per common share	$ 0.10	$ 0.09	$ 0.20	$ 0.18

XML

ACQUISITIONS OF NON-CONTROLLING INTERESTS

6 Months Ended

Jun. 30, 2013

Business Combinations [Abstract]

ACQUISITIONS OF NON-CONTROLLING INTERESTS

4. ACQUISITIONS OF NON-CONTROLLING INTERESTS

In six separate transactions during the six months ended June 30, 2013, the Company purchased partnership interests in five partnerships. The interests in the partnerships purchased ranged from .1% to 35%. The aggregate of the purchase prices paid was $1.2 million, which included $97,000 of undistributed earnings. The remaining purchase price of $1.1 million, less future tax benefits of $415,000, was recognized as an adjustment to additional paid-in capital. For one of the transactions, the non-controlling interest had a $37,000 cumulative loss. This loss less the tax benefit of $14,000 was charged to additional paid-in capital. During the six months ended June 30, 2013, the Company sold a 1% interest in two separate partnerships for an aggregate price of $112,000. This amount, less tax effect of $34,000, was credited to additional paid-in capital.

Included in the above purchases of partnership interests, the Company purchased the remaining 1.3% of the non-controlling interest in STAR Physical Therapy, LP, a subsidiary of the Company (“STAR”) held by Mr. Regg Swanson, the Managing Director and a founder of STAR and a member of the Board (“Swanson”). The purchase price paid for the 1.3% interest was $801,640, which included $55,000 of undistributed earnings. The purchase price was determined based on the contractual terms in the Reorganization of Securities Purchase Agreement dated as of September 6, 2007 among the Company, STAR, the limited partners of STAR and Swanson as Seller Representative and in his individual capacity, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 7, 2007. After this transaction, Swanson does not hold any interest in STAR.

XML

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Numerator:
Net income attributable to common shareholders	$ 4,914	$ 4,849	$ 8,635	$ 9,327
Denominator:
Denominator for basic earnings per share - weighted-average shares	12,089	11,781	12,022	11,754
Effect of dilutive securities - Stock options	21	122	22	118
Denominator for diluted earnings per share - adjusted weighted-average shares	12,110	11,903	12,044	11,872
Earnings per share attributable to common shareholders:
Basic	$ 0.41	$ 0.41	$ 0.72	$ 0.79
Diluted	$ 0.41	$ 0.41	$ 0.72	$ 0.79

XML

ACQUISITIONS OF BUSINESSES (Tables)

6 Months Ended

Jun. 30, 2013

Text Block [Abstract]

Schedule of Preliminary Purchase Prices Allocation

The purchase prices have been preliminarily allocated as follows (in thousands):

Cash paid, net of cash acquired	$	9,998
Seller notes		800
Total consideration	$	10,798
Estimated fair value of net tangible assets acquired:
Total current assets	$	1,349
Total non-current assets		719
Total liabilities		(242	)
Net tangible assets acquired		1,826
Goodwill		14,400
Fair value of noncontrolling interest		(5,428	)
	$	10,798

The purchase prices for the acquisitions in 2012 have been allocated as follows (in thousands):

Cash paid, net of cash acquired	$	7,929
Seller notes		350
Total consideration	$	8,279
Estimated fair value of net tangible assets acquired:
Total current assets	$	363
Total non-current assets		478
Total liabilities		(290	)
Net tangible assets acquired	$	551
Tradenames		1,300
Referral relationships		857
Non competition agreements		265
Goodwill		8,198
Fair value of noncontrolling interest		(2,892	)
	$	8,279

XML

Common Stock - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013	Mar. 31, 2009	Dec. 31, 2008
Statement Of Partners Capital [Abstract]
Common stock authorized by the Board of Directors			2,250,000
Maximum percentage of repurchase of common stock		10.00%
Repurchase of common stock		1,200,000
Bank credit agreement to permit share repurchases of common stock		$ 15,000,000
Total purchased shares	859,499
Additional estimated shares	340,501

XML

Acquisitions of Non-controlling Interests - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013 Partnership Transactions	Feb. 28, 2013	May 22, 2012
Business Acquisition [Line Items]
Number of separate transactions to purchase partnership interest	6
Number of partnership in which interest acquired	5
Purchase price for additional non controlling interest	$ 1,200,000
Undistributed earnings	97,000
Consolidation less than wholly owned subsidiary parent ownership interest amount changes purchase consideration charge from undistributed earning	1,100,000
Future tax benefits	415,000
Aggregate losses attributable to non controlling interest	37,000
Aggregate losses tax effect attributable to non controlling interest	14,000
Consolidation less than wholly owned subsidiary parent ownership interest changes sale of interest percent by parent	1.00%
Proceeds from divestiture of interest in consolidated subsidiaries	112,000
Percentage of purchase of non controlling interest	100.00%	100.00%	70.00%
Income tax effects on sale of interest in partnership	34,000
Business acquisition, cost of acquired entity	95,000	5,000
STAR Physical Therapy, LP [Member]
Business Acquisition [Line Items]
Undistributed earnings	55,000
Percentage of purchase of non controlling interest	1.30%
Business acquisition, cost of acquired entity	$ 801,640
Minimum [Member]
Business Acquisition [Line Items]
Percentage of purchase of non controlling interest	0.10%
Maximum [Member]
Business Acquisition [Line Items]
Percentage of purchase of non controlling interest	35.00%

XML

Acquisition of Businesses - Schedule of Preliminary Purchase Price Allocation (Detail) (USD $)	1 Months Ended	6 Months Ended		12 Months Ended
	Feb. 28, 2013	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	May 22, 2012
Business Combinations [Abstract]
Cash paid, net of cash acquired	$ 9,998,000	$ 9,998,000	$ 7,180,000	$ 7,929,000
Seller notes	800,000			350,000	250,000
Total consideration	10,798,000			8,279,000
Estimated fair value of net tangible assets acquired:
Total current assets	1,349,000			363,000
Total non-current assets	719,000			478,000
Total liabilities	(242,000)			(290,000)
Net tangible assets acquired	1,826,000			551,000
Tradenames		1,300,000		1,300,000
Referral relationships		800,000		857,000
Non competition agreements				265,000
Goodwill	14,400,000			8,198,000
Fair value of noncontrolling interest	(5,428,000)			(2,892,000)
Total consideration	$ 10,798,000			$ 8,279,000

XML

Notes Payable and Revolving Credit Agreement - Summary of Notes Payable (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Proforma Debt Instrument [Line Items]
Payments/Long term debt, Total	$ 16,950	$ 18,034
Less current portion	(800)	(459)
Long term portion	16,150	17,575
Credit Facility [Member]
Proforma Debt Instrument [Line Items]
Payments/Long term debt, Total	15,750	17,400
3.25 % notes payable due in next year [Member]
Proforma Debt Instrument [Line Items]
Payments/Long term debt, Total	$ 1,200	$ 634

XML

Intangible Assets, Net - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2013
Referral relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	6 years
Referral relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	16 years
Non compete agreements [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	5 years
Non compete agreements [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	6 years

XML

Acquisition of Businesses - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended	12 Months Ended				1 Months Ended		1 Months Ended						6 Months Ended		12 Months Ended			6 Months Ended
	May 31, 2012 Clinic	Jun. 30, 2013 Clinic	Dec. 31, 2012 Clinic Transactions	Feb. 28, 2013	May 22, 2012	May 22, 2012 Seller Note [Member]	Feb. 28, 2013 February 2015 [Member]	Feb. 28, 2013 February 2016 [Member]	Apr. 30, 2013 April 2014 [Member]	Apr. 30, 2013 April 2015 [Member]	May 31, 2013 May 2014 [Member]	May 31, 2012 May 2014 [Member]	May 31, 2013 May 2015 [Member]	May 31, 2012 May 2013 [Member]	Jun. 30, 2013 Non Competition Agreement [Member]	Jun. 30, 2013 Referral relationships [Member]	Dec. 31, 2012 Multi Clinic [Member]	Jun. 30, 2013 Multi Clinic [Member] Non Competition Agreement [Member]	Dec. 31, 2012 Multi Clinic [Member] Non Competition Agreement [Member]	Jun. 30, 2013 February 2013 Acquisition [Member] Installment Clinic	Jun. 30, 2013 April 2013 Acquisition [Member] Clinic Installment	Jun. 30, 2013 May 2013 Acquisition [Member] Clinic Installment
Loans At Acquisition Date [Line Items]
Percentage of purchase of non controlling interest		100.00%		100.00%	70.00%															72.00%	50.00%	80.00%
Cash paid for acquisition of interest in clinic														$ 6,090,000			$ 1,938,000			$ 4,300,000	$ 2,400,000	$ 3,600,000
Business acquisition number of installments to payment of purchase consideration																				2	2	2
Business acquisition, cost of acquired entity		95,000		5,000
Acquisition cost payable in two principal installments including accrued interest							200,000		100,000	100,000	100,000	125,000	100,000	125,000
Seller notes issued for acquisition of interest in clinic			350,000	800,000	250,000			200,000
Number of clinics			7																	9	5	5
Percentage of Tax Deductible Goodwill					70.00%
Accrued interest seller note						3.25%
Tradenames		1,300,000	1,300,000
Purchase price allocated to referral relationships		800,000	857,000														57,000
Purchase price allocated to non-competition agreement			265,000															240,000	25,000
Values assigned being amortized to expense equally over the respective estimated life															6 years	12 years
Number of separate transactions for outpatient therapy practices			7
Number of clinic acquired	7	1
Number or transaction for notes payable purchased			1
Principal amount payable																	100,000
Purchase price allocated to current asset																	43,000
Purchase price allocated to non current asset			478,000	719,000													213,000
Purchase price allocated to goodwill			$ 8,198,000	$ 14,400,000													$ 1,883,000

XML

CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY (USD $) In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total Shareholders' Equity [Member]	Noncontrolling Interests [Member]
Balance at Dec. 31, 2012	$ 134,659	$ 141	$ 37,489	$ 111,321	$ (31,628)	$ 117,323	$ 17,336
Balance, shares at Dec. 31, 2012		14,130			(2,215)
Issuance of restricted stock		175
Compensation expense - restricted stock	1,370		1,370			1,370
Transfer of compensation liability for certain stock issued pursuant to incentive plans	248		248			248
Proceeds from exercise of stock options	20	2	18			20
Proceeds from exercise of stock options, shares		15
Excess tax benefit of equity grants	33		33			33
Purchases of business	5,428						5,428
Acquisition of non controlling interests	(684)		(587)			(587)	(97)
Cash dividends to shareholders	(2,418)			(2,418)		(2,418)
Distributions to noncontrolling interest partners	(4,410)						(4,410)
Net income	12,983			8,635		8,635	4,348
Balance at Jun. 30, 2013	$ 147,229	$ 143	$ 38,571	$ 117,538	$ (31,628)	$ 124,624	$ 22,605
Balance, shares at Jun. 30, 2013		14,320			(2,215)

XML

EARNINGS PER SHARE

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

EARNINGS PER SHARE

2. EARNINGS PER SHARE

The computations of basic and diluted earnings per share for the Company are as follows (in thousands, except per share data):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Numerator:
Net income attributable to common shareholders	$	4,914	$	4,849	$	8,635	$	9,327
Denominator:
Denominator for basic earnings per share - weighted-average shares		12,089		11,781		12,022		11,754
Effect of dilutive securities - Stock options		21		122		22		118
Denominator for diluted earnings per share - adjusted weighted-average shares		12,110		11,903		12,044		11,872
Earnings per share attributable to common shareholders:
Basic	$	0.41	$	0.41	$	0.72	$	0.79
Diluted	$	0.41	$	0.41	$	0.72	$	0.79

All options to purchase shares were included in the diluted earnings per share calculation for the three and six months ended June 30, 2013 and 2012 as the average market prices of the common stock was above the exercise prices. The Company’s restricted stock issued is included in basic and diluted shares for the earnings per share computation from the date of grant.

XML

GOODWILL

6 Months Ended

Jun. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

GOODWILL

5. GOODWILL

The changes in the carrying amount of goodwill consisted of the following (in thousands):

	Six Months Ended June 30, 2013
Beginning balance	$	100,188
Goodwill acquired during the period		14,400
Goodwill allocated to specific assets for business acquired in 2012		(2,340	)
Ending balance	$	112,248

XML

ACQUISITIONS OF BUSINESSES

6 Months Ended

Jun. 30, 2013

Text Block [Abstract]

ACQUISITIONS OF BUSINESSES

3. ACQUISITIONS OF BUSINESSES

The purchase price for the 72% interest in the February 2013 Acquisition was $4.3 million in cash and $400,000 in a seller note, that is payable in two principal installments totaling $200,000 each, plus accrued interest, in February 2014 and 2015. The purchase price for the 50% interest in the April 2013 Acquisition was $2.4 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in April of 2014 and 2015. The purchase price for the 80% interest in the May 2013 Acquisition was $3.6 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in May of 2014 and 2015. On February 1, 2013, through a subsidiary, the Company acquired a 100% interest in a clinic for $5,000 and on June 1, 2013, through another subsidiary, the Company acquired a 100% interest in a clinic for $95,000. The purchase prices have been preliminarily allocated as follows (in thousands):

Cash paid, net of cash acquired	$	9,998
Seller notes		800
Total consideration	$	10,798
Estimated fair value of net tangible assets acquired:
Total current assets	$	1,349
Total non-current assets		719
Total liabilities		(242	)
Net tangible assets acquired		1,826
Goodwill		14,400
Fair value of noncontrolling interest		(5,428	)
	$	10,798

The consideration for each transaction was agreed upon through arm’s length negotiations. Funding for the cash portion of the purchase price was derived from proceeds from the Company’s revolving credit facility.

The results of operations of these acquisitions have been included in the Company’s consolidated financial statements since acquired.

Because these acquisitions occurred during the six months ended June 30, 2013, the purchase price plus the fair value of the non-controlling interest was allocated to the fair value of the assets acquired and liabilities assumed based on the preliminary estimates of the fair values at the acquisition date, with the amount exceeding the estimated fair values being recorded as goodwill. The Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used at June 30, 2013 based on additional information obtained. Changes in the estimated valuation of the tangible and intangible assets acquired and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill.

On May 22, 2012, the Company purchased a 70% interest in a 7 clinic group (“May 2012 Acquisition”). The purchase price for the 70% interest in the May 2012 Acquisition was $6,090,000 in cash and $250,000 in seller notes, that are payable in two principal installments totaling $125,000 each, plus any accrued interest, in May 2013 and 2014. The seller notes accrue interest at 3.25% per annum. For the Company, 70% of the goodwill for the May 2012 Acquisition is tax deductible. During the quarter ended March 31, 2013, the Company determined that the amounts attributable to intangible assets other than goodwill are as follows: tradenames - $1,300,000; referral relationships - $800,000; and non competition agreement - $240,000. The value assigned to referral relationships and the non competion agreements will be amortized over the related expected lives which are estimated to be 12 and six years, respectively.

In addition to the May 2012 Acquisition, in 2012, the Company, through its subsidiaries, purchased 7 outpatient therapy practices in 7 transactions for aggregate cash consideration of $1,938,000 and, in one transaction, a $100,000 note payable. The purchase prices were allocated $43,000 to current assets, $213,000 to non-current assets, $25,000 to non competition agreements, $57,000 to referral relationships and $1,883,000 to goodwill.

The purchase prices for the acquisitions in 2012 have been allocated as follows (in thousands):

Cash paid, net of cash acquired	$	7,929
Seller notes		350
Total consideration	$	8,279
Estimated fair value of net tangible assets acquired:
Total current assets	$	363
Total non-current assets		478
Total liabilities		(290	)
Net tangible assets acquired	$	551
Tradenames		1,300
Referral relationships		857
Non competition agreements		265
Goodwill		8,198
Fair value of noncontrolling interest		(2,892	)
	$	8,279

The purchase price plus the fair value of the non-controlling interest for the 2012 acquisitions was allocated to the fair value of the assets acquired and liabilities assumed based on the fair values at the acquisition date, with the amount exceeding the fair values being recorded as goodwill.

Unaudited proforma consolidated financial information for acquisitions occurring in 2013 and 2012 have not been included as the results were not material to current operations.

XML

Goodwill - Summary of Changes in Carrying Amount of Goodwill (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
Goodwill [Roll Forward]
Beginning balance	$ 100,188
Goodwill acquired during the period	14,400
Goodwill allocated to specific assets for business acquired in 2012	(2,340)
Ending balance	$ 112,248

XML

Intangible Assets, Net - Amortization Expenses (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Finite Lived Intangible Assets Amortization [Line Items]
Total amortization expenses	$ 201	$ 212	$ 457	$ 381
Referral relationships [Member]
Finite Lived Intangible Assets Amortization [Line Items]
Total amortization expenses	116	100	266	178
Non compete agreements [Member]
Finite Lived Intangible Assets Amortization [Line Items]
Total amortization expenses	$ 85	$ 112	$ 191	$ 203

XML

Notes Payable and Revolving Credit Agreement - Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Long Term Debt By Maturity [Abstract]
During the twelve months ended March 31, 2014	$ 800
During the twelve months ended March 31, 2015	400
During the twelve months ended March 31, 2016	15,750
Payments/Long term debt, Total	$ 16,950	$ 18,034

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts, patient accounts receivable	$ 1,469	$ 1,595
Allowance for doubtful accounts, accounts receivable - other	$ 412	$ 514
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	14,319,911	14,129,651
Treasury stock, shares	2,214,737	2,214,737

XML

COMMON STOCK

6 Months Ended

Jun. 30, 2013

Equity [Abstract]

COMMON STOCK

8. COMMON STOCK

From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company’s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, the Company amended the Credit Agreement to permit share repurchases of up to $15,000,000. The Company is required to retire shares purchased under the March 2009 Authorization.

Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. The Credit Agreement was further amended to permit the Company to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of its common stock subject to compliance with covenants. There are currently an additional estimated 340,501 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company’s cash position. The Company did not purchase any shares of its common stock during the three months and six months ended June 30, 2013.

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
OPERATING ACTIVITIES
Net income including noncontrolling interests	$ 12,983	$ 14,126
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	2,730	2,646
Provision for doubtful accounts	2,282	2,397
Equity-based awards compensation expense	1,370	1,043
Loss on sale or abandonment of assets, net	84	83
Deferred income tax	(796)	1,046
Other	33
Changes in operating assets and liabilities:
Increase in patient accounts receivable	(2,542)	(1,613)
Decrease (increase) in accounts receivable - other	4	(400)
Decrease in other assets	3,867	301
Increase (decrease) in accounts payable and accrued expenses	682	(693)
Increase in other liabilities	19	31
Net cash provided by operating activities	20,716	18,967
INVESTING ACTIVITIES
Purchase of fixed assets	(2,394)	(1,943)
Purchase of businesses, net of cash acquired	(9,998)	(7,180)
Acquisitions of noncontrolling interests, net of sales	(1,064)	(726)
Net proceeds on sale of fixed assets and business	15	28
Net cash used in investing activities	(13,441)	(9,821)
FINANCING ACTIVITIES
Distributions to noncontrolling interests	(4,410)	(4,751)
Cash dividends to shareholders	(2,418)	(2,117)
Proceeds from revolving line of credit	62,550	32,400
Payments on revolving line of credit	(64,200)	(35,900)
Payment of notes payable	(234)	(184)
Excess tax benefit from stock options exercised	33	184
Other	20	50
Net cash used in financing activities	(8,659)	(10,318)
Net decrease in cash	(1,384)	(1,172)
Cash - beginning of period	11,671	9,983
Cash - end of period	10,287	8,811
Cash paid during the period for:
Income taxes	1,999	3,886
Interest	237	422
Non-cash investing and financing transactions during the period:
Purchase of business - seller financing portion	$ 800	$ 350

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 10,287	$ 11,671
Patient accounts receivable, less allowance for doubtful accounts of $1,469 and $1,595, respectively	27,564	25,973
Accounts receivable - other, less allowance for doubtful accounts of $412 and $514, respectively	1,700	1,703
Other current assets	1,878	5,975
Total current assets	41,429	45,322
Fixed assets:
Furniture and equipment	37,941	36,316
Leasehold improvements	21,404	20,858
Fixed assets, gross	59,345	57,174
Less accumulated depreciation and amortization	45,588	44,158
Fixed assets, net	13,757	13,016
Goodwill	112,248	100,188
Other intangible assets, net	14,029	12,146
Other assets	967	1,042
Total assets	182,430	171,714
Current liabilities:
Accounts payable - trade	1,275	1,732
Accrued expenses	15,298	14,116
Current portion of notes payable	800	459
Total current liabilities	17,373	16,307
Notes payable	400	175
Revolving line of credit	15,750	17,400
Deferred rent	972	894
Other long-term liabilities	706	2,279
Total liabilities	35,201	37,055
Commitments and contingencies
U. S. Physical Therapy, Inc. shareholders' equity:
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding
Common stock, $.01 par value, 20,000,000 shares authorized, 14,319,911 and 14,129,651 shares issued, respectively	143	141
Additional paid-in capital	38,571	37,489
Retained earnings	117,538	111,321
Treasury stock at cost, 2,214,737 shares	(31,628)	(31,628)
Total U. S. Physical Therapy, Inc. shareholders' equity	124,624	117,323
Noncontrolling interests	22,605	17,336
Total equity	147,229	134,659
Total liabilities and stockholders' equity	$ 182,430	$ 171,714

XML

Intangible Assets, Net - Intangible Assets, Net (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Intangible Assets Net Excluding Goodwill [Line Items]
Total	$ 14,029	$ 12,146
Tradenames [Member]
Intangible Assets Net Excluding Goodwill [Line Items]
Total	9,273	7,973
Referral relationships [Member]
Intangible Assets Net Excluding Goodwill [Line Items]
Total	4,035	3,501
Non compete agreements [Member]
Intangible Assets Net Excluding Goodwill [Line Items]
Total	$ 721	$ 672

XML

Basis of Presentation and Significant Accounting Policies - Schedule of Clinic Acquisition (Detail)	12 Months Ended				6 Months Ended
	Dec. 31, 2012 Clinic	Jun. 30, 2013	Feb. 28, 2013	May 22, 2012	Jun. 30, 2013 February 2013 Acquisition [Member] Clinic	Jun. 30, 2013 April 2013 Acquisition [Member] Clinic	Jun. 30, 2013 May 2013 Acquisition [Member] Clinic
Loans At Acquisition Date [Line Items]
Acquisition date					Feb. 28, 2013	Apr. 30, 2013	May 24, 2013
Percentage of interest acquired		100.00%	100.00%	70.00%	72.00%	50.00%	80.00%
Number of clinics	7				9	5	5

XML

Notes Payable and Revolving Credit Agreement - Summary of Notes Payable (Parenthetical) (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
Credit Facility [Member]
Proforma Debt Instrument [Line Items]
Average effective interest rate	3.00%
3.25 % notes payable due in next year [Member]
Proforma Debt Instrument [Line Items]
Annual installments	$ 800
Percentage of Interest accrues	3.25%

XML

Notes Payable and Revolving Credit Agreement - Additional Information (Detail) (USD $)	6 Months Ended			6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Mar. 18, 2009	Jun. 30, 2013 Minimum [Member]	Jun. 30, 2013 Maximum [Member]	Jun. 30, 2013 Revolving credit agreement average effective interest rate of 3.0% inclusive of unused fee [Member]	Jul. 14, 2011 Revolving credit agreement average effective interest rate of 3.0% inclusive of unused fee [Member]	Jun. 04, 2008 Revolving credit agreement average effective interest rate of 3.0% inclusive of unused fee [Member]	Aug. 27, 2007 Revolving credit agreement average effective interest rate of 3.0% inclusive of unused fee [Member]
Proforma Debt Instrument [Line Items]
Revolving credit facility commitment							$ 75,000,000	$ 50,000,000	$ 30,000,000
Purchase of common stock under credit agreement			15,000,000
Company's consolidated leverage ratio	Less than 1.0 to 1.0
Retirement period of stock repurchased	7 days
Maturity start date	Aug. 31, 2011
Maturity end date	Aug. 31, 2015
Spread on Libor variable rate				1.60%	2.50%
Spread on base variable rate				0.10%	1.00%
Special Dividend	$ 0.40
Percentage of unused commitment fee				0.10%	0.25%
Revolving credit outstanding	16,950,000	18,034,000				15,800,000
Remaining revolving credit outstanding						$ 59,200,000

XML

NOTES PAYABLE AND CREDIT AGREEMENT

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

NOTES PAYABLE AND CREDIT AGREEMENT

7. NOTES PAYABLE AND CREDIT AGREEMENT

Credit Agreement and notes payable as of June 30, 2013 and December 31, 2012 consisted of the following ($ in thousands):

	2013			2012
Credit Agreement average effective interest rate of 3.0% inclusive of unused fee	$	15,750		$	17,400
Various notes payable with $800 plus accrued interest due in the next year interest accrues at 3.25% per annum		1,200			634
		16,950			18,034
Less current portion		(800	)		(459	)
	$	16,150		$	17,575

Effective August 27, 2007, the Company entered into a credit agreement with a commitment for a $30.0 million revolving credit facility which was increased to $50.0 million effective June 4, 2008 and increased to $75.0 million effective July 14, 2011 (the “Credit Agreement”). Effective March 18, 2009, the Credit Agreement was amended to permit the purchase up to $15,000,000 of the Company’s common stock subject to compliance with certain covenants, including the requirement that after giving effect to any stock purchase, the Company’s consolidated leverage ratio (as defined in the Credit Agreement) be less than 1.0 to 1.0 and that any stock repurchased be retired within seven days of purchase. Effective October 13, 2010, the Credit Agreement was amended to extend the maturity date from August 31, 2011 to August 31, 2015. In addition, the Credit Agreement was amended to adjust the pricing grid which is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.6% to 2.5% or the applicable spread over the Base Rate ranging from .1% to 1%. Effective October 24, 2012, the Credit Agreement was amended to permit the Company to purchase, commencing on October 24, 2012, and at all times thereafter, up to $15,000,000 of its common stock subject to compliance with covenants. On December 3, 2012, the Credit Agreement was amended to allow the Company to pay a special dividend of $0.40 per share. The Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common shareholders, capital expenditures and other corporate purposes. Fees under the Credit Agreement include an unused commitment fee ranging from .1% to .25% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement. On June 30, 2013, $15.8 million was outstanding under the Credit Agreement resulting in $59.2 million of availability. As of June 30, 2013, the Company was in compliance with all of the covenants thereunder.

The Company generally enters into various notes payable as a means of financing a portion of its acquisitions and purchases of non-controlling interests. In conjunction with the clinic group acquisitions, the Company entered into several seller notes. See Note 3 to consolidated financial statements – Acquisitions of Businesses.

Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to June 30, 2013 are as follows (in thousands):

During the twelve months ended June 30, 2014	$	800
During the twelve months ended June 30, 2015	$	400
During the twelve months ended June 30, 2016	$	15,750
	$	16,950

XML

Intangible Assets, Net - Intangible Assets, Net (Parenthetical) (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Referral relationships [Member]
Intangible Assets Net Excluding Goodwill [Line Items]
Accumulated amortization	$ 1,483	$ 1,217
Non compete agreements [Member]
Intangible Assets Net Excluding Goodwill [Line Items]
Accumulated amortization	$ 2,039	$ 1,848

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Schedule of Clinic Acquisition

During the six months ended June 30, 2013, the Company acquired the following clinic groups:

Acquisition	Date	% Interest Acquired	Number of Clinics
February 2013 Acquisition	Feb 28	72%	9
April 2013 Acquisition	Apr 30	50%	5
May 2013 Acquisition	May 24	80%	5

XML

INTANGIBLE ASSETS, NET

6 Months Ended

Jun. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS, NET

6. INTANGIBLE ASSETS, NET

Intangible assets, net as of June 30, 2013 and December 31, 2012 consisted of the following (in thousands):

	June 30,		December 31,
	2013		2012
Tradenames	$	9,273	$	7,973
Referral relationships, net of accumulated amortization of $1,483 and $1,217, respectively		4,035		3,501
Non compete agreements, net of accumulated amortization of $2,039 and $1,848, respectively		721		672
	$	14,029	$	12,146

Tradenames, referral relationships and non competition agreements are related to the businesses acquired. The value assigned to tradenames has an indefinite life and is tested at least annually for impairment in conjunction with the Company’s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non competitionagreements are amortized over the respective term of the agreements which range from five to six years.

The following table details the amount of amortization expense recorded for intangible assets for the three and six months ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Referral relationships	$	116	$	100	$	266	$	178
Non compete agreements		85		112		191		203
	$	201	$	212	$	457	$	381

Based on the balance of referral relationships and non competition agreements as of June 30, 2013, the expected amount to be amortized in 2013 and thereafter by year is as follows (in thousands):

Referral Relationships			Non Compete Agreements
	Annual			Annual
Years	Amount		Years	Amount
2013		498	2013		341
2014		462	2014		180
2015		441	2015		180
2016		441	2016		118
2017		441	2017		73
2018		405	2018		20
2019		368
2020		361
2021		336
2022		288
2023		180
2024		80

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries (the “Company”). All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest and a 64% limited partnership interest. The managing therapist of each clinic owns, directly or indirectly, the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as “Clinic Partnership”). To a lesser extent, the Company operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with therapists (hereinafter referred to as “Wholly-Owned Facilities”).

The Company continues to seek to attract physical and occupational therapists who have established relationships with patients and physicians by offering therapists a competitive salary and a share of the profits of the clinic operated by that therapist. The Company has developed satellite clinic facilities of existing clinics, with the result that many Clinic Partnerships and Wholly-Owned Facilities operate more than one clinic location. In addition, the Company has acquired a majority interest in a number of clinics through acquisitions.

During the six months ended June 30, 2013, the Company acquired the following clinic groups:

Acquisition	Date	% Interest Acquired	Number of Clinics
February 2013 Acquisition	Feb 28	72%	9
April 2013 Acquisition	Apr 30	50%	5
May 2013 Acquisition	May 24	80%	5

In addition to the above clinic group acquisitions, the Company, through two of its subsidiaries, acquired two physical therapy clinic practices in two separate transactions (the “Tuck-In Acquisitions”).

As of June 30, 2013, the Company operated 449 clinics in 43 states.

The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.

The Company intends to continue to focus on developing new clinics, on opening satellite clinics where deemed appropriate and pursuing additional acquisition opportunities.

The accompanying unaudited consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions for Form 10-Q. However, the statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. Management believes this report contains all necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. For further information regarding the Company’s accounting policies, please read the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate Controller have certified, that the financial statements included in this report present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented.

Operating results for the three and six months ended June 30, 2013 are not necessarily indicative of the results the Company expects for the entire year. Please also review the Risk Factors section included in our Annual Report on Form 10-K for the year ended December 31, 2012.

Clinic Partnerships

For Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interests, typically owned by the managing therapist, directly or indirectly, are recorded within the balance sheets and income statements as non-controlling interests.

Wholly-Owned Facilities

For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due to the profit sharing therapists. The amount is expensed as compensation and included in clinic operating costs – salaries and related costs. The respective liability is included in current liabilities – accrued expenses on the balance sheet.

Significant Accounting Policies

Long-Lived Assets

Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the related assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the related lease term or estimated useful lives of the assets, which is generally three to five years.

Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the related amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Goodwill

Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital.

The fair value of goodwill and other intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining our reporting units when performing our annual goodwill impairment test.

An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2012, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation in the third quarter of 2012 did not yield any impairment charge.

Non-controlling interests

The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the income statement. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling interest on the deconsolidation date.

When the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.

Revenue Recognition

Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.

The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.

Medicare Reimbursement

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (“MPFS”). The MPFS rates are automatically updated annually based on a formula, called the sustainable growth rate (“SGR”) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through 2013, Centers for Medicare & Medicaid Services (“CMS”) or Congress has taken action to prevent the implementation of SGR formula reductions. For 2012, the Temporary Payroll Tax Cut Continuation Act of 2011 (“TPTC”) delayed application of the SGR for the first two months of the year and the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”) included a measure freezing payment rates at their then current level through December 31, 2012. The American Taxpayer Relief Act of 2012 essentially froze the Medicare physician fee schedule rates at 2012 levels through December 31, 2013, averting a scheduled 26.5% cut as a result of the SGR formula that would have taken effect on January 1, 2013. A reduction in the Medicare physician fee schedule payment rates will occur on January 1, 2014, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.

The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. The American Taxpayer Relief Act of 2012 temporarily delayed the automatic, across-the-board “sequestration” cuts in federal spending imposed by the Budget Control Act of 2011. Effective April 1, 2013, Medicare reimbursement for services furnished on or after April 1, 2013 has been reduced by 2%. The MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. As of July 1, 2013, therapists are required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. For claims submitted after July 1, 2013, CMS will reject claims if the required data is not included in the claim.

As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the “Therapy Cap” or “Limit”) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy. During 2012, the annual Limit on outpatient therapy services was $1,880 for Physical Therapy and Speech Language Pathology Services combined and $1,880 for Occupational Therapy Services. Pursuant to the final MPFS rule for 2013, effective January 1, 2013 the annual Limit on outpatient therapy services is $1,900 for Physical Therapy and Speech Language Pathology Services combined and $1,900 for Occupational Therapy Services. Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the American Taxpayer Relief Act of 2012 extended the annual limits on therapy expenses to services furnished in hospital outpatient department settings from October 1, 2012 through December 31, 2013. Unless Congress enacts legislation to extend the application of these limits to therapy provided in hospital outpatient settings, the Therapy Cap will no longer apply to such services starting as of January 1, 2014.

In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses. Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) is able to request an exception from the Therapy Caps if the provision of therapy services was deemed to be medically necessary. Therapy Cap exceptions have been available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity. The MCTRA extended the exceptions process for outpatient Therapy Caps through December 31, 2012. The American Taxpayer Relief Act of 2012 extended the exceptions process for outpatient Therapy Caps through December 31, 2013. Unless Congress extends the exceptions process, the Therapy Caps will apply to all outpatient therapy services beginning January 1, 2014, except those services furnished and billed by outpatient hospital departments.

Furthermore, under the MCTRA, since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review prior to payment. The $3,700 threshold is applied to the combined physical therapy/speech language pathology cap; a separate $3,700 threshold is applied to the occupational therapy cap. The American Taxpayer Relief Act of 2012 extended through December 31, 2013 the requirement that Medicare perform manual medical review of therapy services beyond the $3,700 threshold and continued the process by which providers may seek pre-approval for services to be performed beyond such dollar threshold. In February 2013, CMS advised providers that the pre-approval process for services beyond the $3,700 cap will no longer be in effect, so that all such services during the calendar year that are over the dollar threshold will be subject to a manual medical review.

CMS adopted a multiple procedure payment reduction (“MPPR”) for therapy services in the final update to the MPFS for calendar year 2011. During 2011, the MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (“RVU”) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increased the payment reduction to 50%, on subsequent therapy procedures in either setting, effective April 1, 2013. This reduction in payment for our services provided to Medicare beneficiaries will negatively impact the Company’s financial results, estimated to represent an 8% to 10% reduction in overall reimbursement for services the Company provides to Medicare beneficiaries.

Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of June 30, 2013. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program.

Physician Services Revenues

Revenues from physician services are generated by franchise arrangements and fees from third parties, pursuant to which there are multiple deliverables — training and ongoing services — as well as through the one physician services facility which is scheduled to close in August 2013. Each component can be purchased separately. Revenue is recognized over the period the respective services are provided. Physician service revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.

Management Contract Revenues

Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.

Contractual Allowances

Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements for such services by both insurance companies and government sponsored healthcare programs. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow it to provide the necessary detail and accuracy with its collectibility estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing systems may not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, the difference between net revenues and corresponding cash collections has historically generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis shows a less than 1% difference between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at June 30, 2013.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Company recognizes accrued interest expense and penalties associated with unrecognized tax benefits as income tax expense. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the three and six months ended June 30, 2013 and 2012.

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount of the Company’s revolving line of credit approximates its fair value. The interest rate on the revolving line of credit, which is tied to the Eurodollar Rate, is set at various short-term intervals as detailed in the credit agreement.

Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.

Use of Estimates

In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.

Self-Insurance Program

The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through June 30, 2013.

Restricted Stock

Restricted stock issued to employees and directors is subject to certain conditions, including continued employment or continued service on our Board of Directors (the “Board”), respectively. The transfer restrictions for shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the service period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.

XML

Intangible Assets, Net - Amortization of Referral Relationships and Non Competition Agreements (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013
Referral relationships [Member]
Finite Lived Intangible Assets Amortization [Line Items]
2013	$ 498
2014	462
2015	441
2016	441
2017	441
2018	405
2019	368
2020	361
2021	336
2022	288
2023	180
2024	80
Non compete agreements [Member]
Finite Lived Intangible Assets Amortization [Line Items]
2013	341
2014	180
2015	180
2016	118
2017	73
2018	$ 20

XML

GOODWILL (Tables)

6 Months Ended

Jun. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill consisted of the following (in thousands):

	Six Months Ended June 30, 2013
Beginning balance	$	100,188
Goodwill acquired during the period		14,400
Goodwill allocated to specific assets for business acquired in 2012		(2,340	)
Ending balance	$	112,248

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Long-Lived Assets

Long-Lived Assets

Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the related assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the related lease term or estimated useful lives of the assets, which is generally three to five years.

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of

Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the related amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Goodwill

Goodwill

Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital.

The fair value of goodwill and other intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining our reporting units when performing our annual goodwill impairment test.

An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2012, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation in the third quarter of 2012 did not yield any impairment charge.

Non-controlling Interests

Non-controlling interests

The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the income statement. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling interest on the deconsolidation date.

When the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.

Revenue Recognition

Revenue Recognition

Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.

The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.

Medicare Reimbursement

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (“MPFS”). The MPFS rates are automatically updated annually based on a formula, called the sustainable growth rate (“SGR”) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through 2013, Centers for Medicare & Medicaid Services (“CMS”) or Congress has taken action to prevent the implementation of SGR formula reductions. For 2012, the Temporary Payroll Tax Cut Continuation Act of 2011 (“TPTC”) delayed application of the SGR for the first two months of the year and the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”) included a measure freezing payment rates at their then current level through December 31, 2012. The American Taxpayer Relief Act of 2012 essentially froze the Medicare physician fee schedule rates at 2012 levels through December 31, 2013, averting a scheduled 26.5% cut as a result of the SGR formula that would have taken effect on January 1, 2013. A reduction in the Medicare physician fee schedule payment rates will occur on January 1, 2014, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.

The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. The American Taxpayer Relief Act of 2012 temporarily delayed the automatic, across-the-board “sequestration” cuts in federal spending imposed by the Budget Control Act of 2011. Effective April 1, 2013, Medicare reimbursement for services furnished on or after April 1, 2013 has been reduced by 2%. The MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. As of July 1, 2013, therapists are required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. For claims submitted after July 1, 2013, CMS will reject claims if the required data is not included in the claim.

As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the “Therapy Cap” or “Limit”) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy. During 2012, the annual Limit on outpatient therapy services was $1,880 for Physical Therapy and Speech Language Pathology Services combined and $1,880 for Occupational Therapy Services. Pursuant to the final MPFS rule for 2013, effective January 1, 2013 the annual Limit on outpatient therapy services is $1,900 for Physical Therapy and Speech Language Pathology Services combined and $1,900 for Occupational Therapy Services. Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the American Taxpayer Relief Act of 2012 extended the annual limits on therapy expenses to services furnished in hospital outpatient department settings from October 1, 2012 through December 31, 2013. Unless Congress enacts legislation to extend the application of these limits to therapy provided in hospital outpatient settings, the Therapy Cap will no longer apply to such services starting as of January 1, 2014.

In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses. Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) is able to request an exception from the Therapy Caps if the provision of therapy services was deemed to be medically necessary. Therapy Cap exceptions have been available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity. The MCTRA extended the exceptions process for outpatient Therapy Caps through December 31, 2012. The American Taxpayer Relief Act of 2012 extended the exceptions process for outpatient Therapy Caps through December 31, 2013. Unless Congress extends the exceptions process, the Therapy Caps will apply to all outpatient therapy services beginning January 1, 2014, except those services furnished and billed by outpatient hospital departments.

Furthermore, under the MCTRA, since on October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review prior to payment. The $3,700 threshold is applied to the combined physical therapy/speech language pathology cap; a separate $3,700 threshold is applied to the occupational therapy cap. The American Taxpayer Relief Act of 2012 extended through December 31, 2013 the requirement that Medicare perform manual medical review of therapy services beyond the $3,700 threshold and continued the process by which providers may seek pre-approval for services to be performed beyond such dollar threshold. In February 2013, CMS advised providers that the pre-approval process for services beyond the $3,700 cap will no longer be in effect, so that all such services during the calendar year that are over the dollar threshold will be subject to a manual medical review.

CMS adopted a multiple procedure payment reduction (“MPPR”) for therapy services in the final update to the MPFS for calendar year 2011. During 2011, the MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (“RVU”) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increased the payment reduction to 50%, on subsequent therapy procedures in either setting, effective April 1, 2013. This reduction in payment for our services provided to Medicare beneficiaries will negatively impact the Company’s financial results, estimated to represent an 8% to 10% reduction in overall reimbursement for services the Company provides to Medicare beneficiaries.

Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of June 30, 2013. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program.

Physician Services Revenues

Revenues from physician services are generated by franchise arrangements and fees from third parties, pursuant to which there are multiple deliverables — training and ongoing services — as well as through the one physician services facility which is scheduled to close in August 2013. Each component can be purchased separately. Revenue is recognized over the period the respective services are provided. Physician service revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.

Management Contract Revenues

Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.

Contractual Allowances

Contractual Allowances

Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements for such services by both insurance companies and government sponsored healthcare programs. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow it to provide the necessary detail and accuracy with its collectibility estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing systems may not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, the difference between net revenues and corresponding cash collections has historically generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis shows a less than 1% difference between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at June 30, 2013.

Income Taxes

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Company recognizes accrued interest expense and penalties associated with unrecognized tax benefits as income tax expense. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the three and six months ended June 30, 2013 and 2012.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount of the Company’s revolving line of credit approximates its fair value. The interest rate on the revolving line of credit, which is tied to the Eurodollar Rate, is set at various short-term intervals as detailed in the credit agreement.

Segment Reporting

Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.

Use of Estimates

Use of Estimates

In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.

Self-Insurance Program

Self-Insurance Program

The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through June 30, 2013.

Restricted Stock

Restricted Stock

Restricted stock issued to employees and directors is subject to certain conditions, including continued employment or continued service on our Board of Directors (the “Board”), respectively. The transfer restrictions for shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the service period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.

XML

Basis of Presentation and Significant Accounting Policies - Additional information (Detail) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended				12 Months Ended	6 Months Ended
	May 31, 2012 Clinic	Jun. 30, 2013 State Clinic	Jun. 30, 2012	Jun. 30, 2013 Facility Clinic State	Jun. 30, 2012	Jun. 30, 2013 Minimum [Member]	Jun. 30, 2013 Maximum [Member]	Dec. 31, 2012 Maximum [Member]	Jun. 30, 2013 Furniture & equipment [Member] Minimum [Member]	Jun. 30, 2013 Furniture & equipment [Member] Maximum [Member]	Jun. 30, 2013 Computer Software, Intangible Asset [Member] Minimum [Member]	Jun. 30, 2013 Computer Software, Intangible Asset [Member] Maximum [Member]	Jun. 30, 2013 Leasehold improvements [Member] Minimum [Member]	Jun. 30, 2013 Leasehold improvements [Member] Maximum [Member]
Depreciation Amortization Impairment [Line Items]
Percentage of general partnership interest owned				1.00%
Percentage of limited partnership interest owned				64.00%
Number of clinic acquired	7			1
Number of clinics operated		449		449
Number of states where clinics are operated		43		43
Estimated useful lives									3 years	8 years	3 years	7 years	3 years	5 years
Percentage of reduction prevented				26.50%
Effective date of reduction in Medicare physician fee payment rate				Apr. 01, 2013
Federal debt ceiling in connection with deficit reductions				10 years
Reductions in federal spending				$ 1,200,000,000,000
Medicare spending cut percentage				2.00%
Expected reduction in Medicare spending percentage		2.00%		2.00%
Annual limit on physical therapy and speech language pathology services							1,900	1,880
Annual limit occupational therapy services							1,900	1,880
Combined physical therapy/speech language pathology expenses						3,700
Occupational therapy cap expenses						3,700
Percentage of practice expense component				100.00%
Percentage reduction for service				20.00%
Percentage reduction for service in institutional settings				25.00%
Reduction in overall reimbursement for services Company provides to Medicare beneficiaries.						8.00%	10.00%
Percentage of increased payment reduction				50.00%
Number of physician services facilities				1
Difference between net revenues and corresponding cash collections, approximately of net revenues				1.00%
Maximum difference between actual aggregate contractual reserve and estimated contractual allowance reserve				1.00%
Minimum difference between actual aggregate contractual reserve and estimated contractual allowance reserve				1.00%
Minimum percentage of fair value reporting unit less than carrying amount				50.00%
Accrued interest and penalties associated with any unrecognized tax benefits		0	0	0	0
Unrecognized tax benefit		0	0	0	0
Interest expense recognized		$ 0	$ 0	$ 0	$ 0
Shares granted to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant				Shares granted to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant.

XML

INTANGIBLE ASSETS, NET (Tables)

6 Months Ended

Jun. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

Intangible assets, net as of June 30, 2013 and December 31, 2012 consisted of the following (in thousands):

	June 30,		December 31,
	2013		2012
Tradenames	$	9,273	$	7,973
Referral relationships, net of accumulated amortization of $1,483 and $1,217, respectively		4,035		3,501
Non compete agreements, net of accumulated amortization of $2,039 and $1,848, respectively		721		672
	$	14,029	$	12,146

Amortization Expenses

The following table details the amount of amortization expense recorded for intangible assets for the three and six months ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Referral relationships	$	116	$	100	$	266	$	178
Non compete agreements		85		112		191		203
	$	201	$	212	$	457	$	381

Amortization of Referral Relationships and Non Competition Agreements

Based on the balance of referral relationships and non competition agreements as of June 30, 2013, the expected amount to be amortized in 2013 and thereafter by year is as follows (in thousands):

Referral Relationships			Non Compete Agreements
	Annual			Annual
Years	Amount		Years	Amount
2013		498	2013		341
2014		462	2014		180
2015		441	2015		180
2016		441	2016		118
2017		441	2017		73
2018		405	2018		20
2019		368
2020		361
2021		336
2022		288
2023		180
2024		80

XML

Document and Entity Information	6 Months Ended
	Jun. 30, 2013	Aug. 08, 2013
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	USPH
Entity Registrant Name	U S PHYSICAL THERAPY INC /NV
Entity Central Index Key	0000885978
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		12,106,424

XML

NOTES PAYABLE AND CREDIT AGREEMENT (Tables)

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Summary of Credit Agreement and Notes Payable

Credit Agreement and notes payable as of June 30, 2013 and December 31, 2012 consisted of the following ($ in thousands):

	2013			2012
Credit Agreement average effective interest rate of 3.0% inclusive of unused fee	$	15,750		$	17,400
Various notes payable with $800 plus accrued interest due in the next year interest accrues at 3.25% per annum		1,200			634
		16,950			18,034
Less current portion		(800	)		(459	)
	$	16,150		$	17,575

Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility

Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to June 30, 2013 are as follows (in thousands):

During the twelve months ended June 30, 2014	$	800
During the twelve months ended June 30, 2015	$	400
During the twelve months ended June 30, 2016	$	15,750
	$	16,950